RBOT · Vicarious Surgical Inc.
Market Cap
$284,969
Shares
7.12M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$50.18M
+20.6%
FY2025
Diluted EPS
-$14.70
-1325%
FY2023
Operating Cash Flow
-$45.08M
+9.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $33.6M | $40.16M | $47.58M | $43.9M | $22.06M | $9.8M | |
| — | $2.17M | $4.53M | $6.23M | $6.46M | $2.96M | $861K | |
| — | $15.2M | $21.88M | $26.86M | $29.72M | $13.2M | $2.33M | |
| — | $50.03M | $66.56M | $80.67M | $80.08M | $38.22M | $12.99M | |
| — | -$50.03M | -$66.56M | -$80.67M | -$80.08M | -$38.22M | -$12.99M | |
| — | — | — | $25K | $200K | $89K | $3000 | |
| — | — | — | — | $1.44M | $20K | $113K | |
| — | -$155K | $3.33M | — | — | — | — | |
| — | -$50.18M | -$63.22M | -$71.07M | $5.16M | -$35.21M | -$12.88M | |
| — | -$50.18M | -$63.22M | -$71.07M | $5.16M | -$35.21M | -$12.88M | |
| — | — | — | — | $5.16M | -$35.21M | -$12.88M | |
| — | -$50.23M | -$63.18M | -$71.06M | $5.16M | — | — | |
| USD/shares | -$10.37 | — | — | -$14.70 | $1.20 | -$10.80 | -$4.80 |
| USD/shares | -$10.37 | — | — | -$14.70 | $1.20 | -$10.80 | -$4.80 |
| shares | — | 6.13M | 5.89M | 4.87M | 4.06M | 3.22M | — |
| shares | — | 6.13M | 5.89M | 4.87M | 4.25M | 3.22M | 2.62M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Medical Devices median 2.52×
EV/EBIT
—
Medical Devices median 21.77×
P/E (TTM)
—
Medical Devices median 29.48×